Vericel (VCEL) Change in Inventory (2014 - 2026)
Vericel (VCEL) posted Change in Inventory of $183000.0 for Q2 2026, down 81.02% sequentially from $964000.0 in Q1 2026, and up 166.55% YoY from $68656.2 in Q2 2025.
Analysis
Vericel (VCEL) Change in Inventory (2014 - 2026) Analysis & Trends
Vericel has reported Change in Inventory for 13 years, with the latest figure at $183000.0 in Q2 2026.
- Quarterly Change in Inventory rose 166.55% year-over-year to $183000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.9 million (up 50.15% YoY) and the FY2025 annual result came in at $1.2 million, down 71.3% from the prior year.
- Change in Inventory fell to $183000.0 in Q2 2026 per VCEL's latest filing, from $964000.0 in the prior quarter.
- Over five years, Change in Inventory peaked at $1.6 million in Q4 2024 and troughed at -$1.5 million in Q2 2023.
- A 5-year average of $353833.3 and a median of $468000.0 in 2023 frame the typical range for Change in Inventory.
- The widest YoY moves for Change in Inventory: up 700.0% in 2022, down 330.75% in 2022.
- Over 5 years, Change in Inventory stood at -$743000.0 in 2022, then jumped by 162.72% to $466000.0 in 2023, then jumped by 247.0% to $1.6 million in 2024, then slumped by 72.29% to $448000.0 in 2025, then slumped by 59.15% to $183000.0 in 2026.
- According to Business Quant data, Change in Inventory over the past three periods registered $183000.0, $964000.0, and $448000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 27.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 28.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 132.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 47.15 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -280,000.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 12.97 Mn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | 183,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 183,000.00 |
| Mar 31, 2026 | 964,000.00 |
| Dec 31, 2025 | 448,000.00 |
| Sep 30, 2025 | 1.32 Mn |
| Jun 30, 2025 | -275,000.00 |
| Mar 31, 2025 | -267,000.00 |
| Dec 31, 2024 | 1.62 Mn |
| Sep 30, 2024 | 869,000.00 |
| Jun 30, 2024 | 1.33 Mn |
| Mar 31, 2024 | 470,000.00 |
| Dec 31, 2023 | 466,000.00 |
| Sep 30, 2023 | -1.26 Mn |
| Jun 30, 2023 | -1.49 Mn |
| Mar 31, 2023 | -616,000.00 |
| Dec 31, 2022 | -743,000.00 |
| Sep 30, 2022 | 800,000.00 |
| Jun 30, 2022 | 1.54 Mn |
| Mar 31, 2022 | 1.00 Mn |
| Dec 31, 2021 | 322,000.00 |
| Sep 30, 2021 | 100,000.00 |